問卷

TPIDB > Principal Investigator

Principal Investigator


China Medical University Hospital (在職)

Division of Cardiovascular Diseases

更新時間:2023-09-19

林晏年
  • Co-Principal Investigator
  • Clinical Trial Experience (year)

篩選

List

33Cases

2025-11-14 - 2031-03-30

Active
A Phase 3 Randomized, Double-blind, Placebo-controlled Study to Evaluate the Efficacy and Safety of Maridebart Cafraglutide on Mortality and Morbidity in Participants Living With Heart Failure With Preserved or Mildly Reduced Ejection Fraction and Obesity (MARITIME-HF)
  • Condition/Disease

    Heart Failure With Preserved Ejection Fraction、 Heart Failure With Mildly Reduced Ejection Fraction Obesity

  • Test Drug

    subcutaneous injection

Participate Sites
6Sites

Not yet recruiting6Sites

2025-07-01 - 2030-12-31

Active
  • Condition/Disease

  • Test Drug

Participate Sites
23Sites

Recruiting23Sites

2024-03-01 - 2027-12-31

Phase III

Active
  • Condition/Disease

  • Test Drug

Participate Sites
21Sites

Not yet recruiting11Sites

Recruiting9Sites

2024-02-01 - 2028-12-31

Phase III

  • Condition/Disease

  • Test Drug

Participate Sites
10Sites

Recruiting10Sites

2025-03-01 - 2030-06-30

Active
  • Condition/Disease

  • Test Drug

Participate Sites
18Sites

Recruiting18Sites

2021-05-01 - 2025-12-31

Phase II/III

Completed
  • Condition/Disease

  • Test Drug

Participate Sites
14Sites

Recruiting12Sites

Terminated1Sites

2023-10-01 - 2026-12-31

Phase III

Active
  • Condition/Disease

  • Test Drug

Participate Sites
9Sites

Not yet recruiting4Sites

Recruiting5Sites

2022-06-01 - 2024-12-31

Phase III

Completed
  • Condition/Disease

  • Test Drug

Participate Sites
12Sites

Not yet recruiting4Sites

Recruiting8Sites

2023-10-02 - 2030-09-30

Phase III

Active
  • Condition/Disease

  • Test Drug

Participate Sites
10Sites

Recruiting10Sites

2023-05-01 - 2028-07-31

Phase II

Active
  • Condition/Disease

  • Test Drug

Participate Sites
2Sites

Recruiting2Sites

1 2 3 4